Impax pays $2m upfront for Durect's Eladur pain patch
This article was originally published in Scrip
Executive Summary
Impax Laboratories in Hayward, California paid $2m upfront and committed up to $61m in development and commercial milestone fees plus tiered royalties for exclusive worldwide rights to Durect's investigational transdermal bupivacaine patch Eladur for the treatment of pain associated with post-herpetic neuralgia (PHN).